Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nanocurcumin for prevention of cisplatin-induced nephrotoxicity in cancer patients
IRCT20200408046990N11Phase 2Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- May 2020
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2 trial of nanocurcumin in Cisplatin-Induced Nephropathy, sponsored by Mashhad University of Medical Sciences. Started May 2020; status: completed.
02
Drugs
nanocurcumin
03
Conditions
Cisplatin-Induced Nephropathy
Beyond the preview
Go deeper on IRCT20200408046990N11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200408046990N11.